AGH 3.25 0.00 Vol 0 AGL 24.01 0.00 Vol 0 BAS 1.5 0.00 Vol 0 BFM 17.05 0.00 Vol 0 BG23B 97.4999 0.00 Vol 0 BPH 6.4 0.00 Vol 0 DEVON 5.25 0.00 Vol 0 LOM 2.77 0.00 Vol 0 NTB 33.35 0.00 Vol 0 ONE 3.65 0.00 Vol 0 POLAR 5.1 0.00 Vol 0 SOM 15 1.00 Vol 1200 WHHL 3.75 0.00 Vol 0 WWW 23 1.50 Vol 1000
Market Closed:


Hamilton, Bermuda – 8 November 2018 – In a filing with the Bermuda Stock Exchange (“BSX”), Jazz Pharmaceuticals plc (Nasdaq: JAZZ) whose Secured Loan Notes are listed on the BSX announced 2018 third quarter financial results.  The full filing stated:


GAAP Diluted EPS of $2.41; Adjusted Diluted EPS of $3.58 Reflects Growth of 11%

Total Revenues Increased 14% to $469 Million

Xyrem Product Sales Increased 18% to $357 Million

Received EU Marketing Authorization for Vyxeos and Initiated Rolling Launch

ANDA Filer Settlement Reached, Resolving Outstanding Xyrem Patent Litigation Received

FDA Approval of Xyrem for Pediatric Narcolepsy Patients


DUBLIN, November 6, 2018 -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2018 and updated financial guidance for 2018.

“We delivered strong top-line and bottom-line growth in the third quarter and recently achieved two significant regulatory milestones, with the receipt of marketing authorization for Vyxeos in the EU and FDA approval of Xyrem for pediatric narcolepsy patients,” said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals. “In the U.S., we are reinforcing Vyxeos as essential therapy for secondary AML with increased education and outreach programs to address the complex and evolving marketplace for AML. As we approach year end, we are also focused on our remaining 2018 corporate goals, including our planned solriamfetol EU regulatory submission and expected FDA approval of solriamfetol.”

GAAP net income for the third quarter of 2018 was $149.3 million, or $2.41 per diluted share, compared to $63.5 million, or $1.03 per diluted share, for the third quarter of 2017.

Adjusted net income for the third quarter of 2018 was $221.7 million, or $3.58 per diluted share, compared to $197.6 million, or $3.22 per diluted share, for the third quarter of 2017. Reconciliations ofapplicable GAAP reported to non-GAAP adjusted information are included at the end of this press release.

The full press release can be found by using the following link:







Kathee Littrell

Vice President, Investor Relations Jazz Pharmaceuticals plc

Ireland, +353 1 634 7887

U.S., +1 650 496 2717



Jacqueline Kirby

Vice President, Corporate Affairs & Government Relations Jazz Pharmaceuticals plc

Ireland, +353 1 697 2141

U.S., +1 215 867 4910


08:30-09:00 Price Discovery
09:00-16:30 Continuous Trading


TEL: +1 (441) 292 7212
FAX: +1 (441) 292 7619


30 Victoria Street
3rd Floor
Hamilton, Bermuda


P.O. Box HM 1369
Hamilton HMFX



The information contained in these pages has been obtained from sources which The Bermuda Stock Exchange believes are reliable. However, the accuracy of the information cannot and is not guaranteed and The Bermuda Stock Exchange makes no representation as to its accuracy or completeness. Neither this Web site, nor any information contained herein, constitutes advice or a solicitation to subscribe, purchase or sell any securities. The Bermuda Stock Exchange expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon any part of the contents of this site or any external sites referenced from this website.